Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CTSV | O60911 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128434 | 0.86 | CYP1A2 (0.40) | KMT2AMAPTALOX5LMNA | |
| SCHEMBL1534099 | 0.86 | MEN1 (0.49) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL6125199 | 0.85 | PTPN1 (0.47) | MEN1KMT2APTPN1LMNAHPGD | |
| SCHEMBL9279822 | 0.85 | PTPN1 (0.44) | MEN1KMT2APTPN1LMNAHPGD | |
| SCHEMBL1534206 | 0.85 | MEN1 (0.42) | PTGESMEN1KMT2AMAPTCTSV | |
| SCHEMBL18373058 | 0.83 | ALOX5 (0.48) | MEN1KMT2AMAPTALOX5LMNA | |
| SCHEMBL113286 | 0.82 | PTPN1 (0.42) | MEN1KMT2AMAPTPTPN1LMNA | |
| SCHEMBL114105 | 0.82 | THRA (0.46) | MAPTPTPN1LMNAHPGD | |
| SCHEMBL9283029 | 0.82 | KDM4E (0.46) | MAPTPTPN1LMNAHPGD | |
| SCHEMBL113312 | 0.81 | ALOX5 (0.46) | MEN1KMT2AMAPTALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115448849-B | Preparation method of 2-benzyloxy-3-dibenzylamino-5-fluoro-6-methylbenzoic acid phenyl ester | 苏州富士莱医药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115448849-A | Preparation method of 2-benzyloxy-3-dibenzylamino-5-fluoro-6-methyl benzoate | 苏州富士莱医药股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170275244-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-8501716-B2 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2424834-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | President and Fellows of Harvard College (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TET1, TET3, TYMS | PTGES 242/4885MEN1 1602/4885KMT2A 2160/4885 |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | PTGES 2190/4885MEN1 1746/4885KMT2A 1697/4885 |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | PTGES 1415/4885MEN1 2745/4885KMT2A 2833/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | PTGES 1415/4885MEN1 2745/4885KMT2A 2833/4885 |
| US-20170275244-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | PTGES 4057/4885MEN1 2309/4885KMT2A 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.